SCHEMBL297475

SCHEMBL297475

[CH2]Cc1cc(-c2ccccc2C(=O)O)cc(-c2ccccc2C(=O)O)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 2/20 0.49
LTB4R2 Q9NPC1 6/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
ALOX12 P18054 1/20 0.45
BRS3 P32247 1/20 0.44
ALDH1A1 P00352 1/20 0.43
ALOX15 P16050 1/20 0.43
HNF4A P41235 1/20 0.43
ERN1 O75460 1/20 0.43
MYC P01106 1/20 0.42
UCHL5 Q9Y5K5 1/20 0.42
PTPN11 Q06124 1/20 0.42
BCAT2 O15382 1/20 0.42
PTPN2 P17706 1/20 0.41
PTPN1 P18031 1/20 0.41
PTPN6 P29350 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL139845 0.85 ALDH1A1 (0.59) FOLH1NPC1RAB9ASMN1; SMN2CYP3A4
SCHEMBL30047867 0.85 ALDH1A1 (0.59) FOLH1NPC1RAB9ASMN1; SMN2CYP3A4
SCHEMBL296448 0.80 ALDH1A1 (0.48) FOLH1LTB4R2NPC1RAB9ASMN1; SMN2
SCHEMBL689031 0.77 HNF4A (0.62) FOLH1NPC1RAB9ASMN1; SMN2CYP3A4
SCHEMBL21840413 0.77 MYC (0.50) FOLH1NPC1RAB9ASMN1; SMN2CYP3A4
SCHEMBL20914432 0.76 BRS3 (0.45) FOLH1NPC1RAB9ASMN1; SMN2CYP2C9
SCHEMBL30010399 0.76 PTPN1 (0.56) LTB4R2NPC1RAB9ASMN1; SMN2BRS3
SCHEMBL18759613 0.75 HNF4A (0.63) LTB4R2NPC1RAB9ASMN1; SMN2CYP3A4
Benzene SCHEMBL1403559 0.75 HNF4A (0.69) FOLH1LTB4R2NPC1RAB9ASMN1; SMN2
Benzene SCHEMBL28480917 0.75 HNF4A (0.69) FOLH1LTB4R2NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501897-B1 METHOD FOR THE PRODUCTION OF PERYLEN-3,4:9,10-TETRACARBOXYLIC ACID DIIMIDES AND PERYLEN-3,4:9,10-TETRACARBOXYLIC ACID DIANHYDRIDE AND NAPHTALENE-1,8-DICARBOXYLIMIDES BASF SE (DE) 2012-03-14 EP disclosed
US-7807836-B2 Preparation of perylen-3,4:9,10-tetracarboxylic dianhydride and also of naphtalene-1,8-dicarboximides BASF AKTIENGESELLSCHAFT (DE) 2010-10-05 US disclosed
US-20080161569-A1 PREPARATION OF PERYLEN-3,4:9,10-TETRACARBOXYLIC DIANHYDRIDE AND ALSO OF NAPHTALENE-1,8-DICARBOXIMIDES BASF AKTIENGESELLSCHAFT (DE) 2008-07-03 US disclosed
US-7393956-B2 Method for the production of perylen-3,4:9,10-tetracarboxylic acid diimides and perylen-3,4:9,10-tetracarboxylic acid dianhydride and naphtalene-1,8-dicarboxylimides BASF AKTIENGESELLSCHAFT (DE) 2008-07-01 US disclosed
US-20050131220-A1 Method for the production of perylen-3,4:9,10-tetracarboxylic acid diimides and perylen-3,4:9,10-tetracarboxylic acid dianhydride and naphtalene-1,8-dicarboxylimides BASF AKTIENGESELLSCHAFT (DE) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161569-A1 PREPARATION OF PERYLEN-3,4:9,10-TETRACARBOXYLIC DIANHYDRIDE AND ALSO OF NAPHTALENE-1,8-DICARBOXIMIDES CLIC1, PNPO, CLIC4 FOLH1 3521/4885LTB4R2 268/4885NPC1 3331/4885
US-20050131220-A1 Method for the production of perylen-3,4:9,10-tetracarboxylic acid diimides and perylen-3,4:9,10-tetracarboxylic acid dianhydride and naphtalene-1,8-dicarboxylimides CBR1, CBR3, SCO2 FOLH1 3657/4885LTB4R2 164/4885NPC1 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.